CDKN2B and acute myeloid leukemia: Furthermore, alterations to the interplay between DNA methylation and modifications to H3K4/K27 contribute to the altered expression of the cyclin-dependent kinase inhibitor 2B (CDKN2B or p15) gene observed in acute myeloid leukemia (AML) (9).